Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab added to TPF induction and chemoradiotherapy for inoperable oral squamous cell carcinoma
ISRCTN13782908Phase 2Completed
- Sponsor
- Taipei Veterans General Hospital
- Start
- Sep 2015
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cetuximab, docetaxel, cisplatin and fluorouracil in Oral Mucosal Carcinoma, sponsored by Taipei Veterans General Hospital. Primary endpoint: Objective response rate of induction chemotherapy. Started Sep 2015; status: completed.
02
Drugs
cetuximabdocetaxelcisplatinfluorouracil
03
Conditions
Oral Mucosal Carcinoma
Beyond the preview
Go deeper on ISRCTN13782908.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN13782908.